StockWatch
·
HIRECT · Q2 FY27 · THE VERDICT

Record Revenue Growth Masks a Profitability Collapse

HIRECT delivered 39% YoY revenue growth, beating the 30% FY27 guidance. But PAT cratered 80.5%. The margin story — raw material inflation, unfavorable product mix, and a French acquisition losing ₹10 Cr a quarter — explains the gap, and signals 2–3 more quarters of pain ahead.

Q2 FY27 resultsHIRECTHIND RECTIFIERS LTD.17 Nov 2026 · 6 min read

On the surface, HIRECT's Q2 looks like a winner: revenue hit ₹315.7 Cr, up 39% year-over-year, comfortably beating the 30% FY27 growth target. But the profit side tells a different story. PAT collapsed to ₹2.9 Cr, down 80.5% from last year—a loss of organic earnings power that revenue growth simply masks. The consolidated EBITDA margin shrank to 4.3%, versus the 10.6–10.8% standalone guidance management gave last quarter. That gap is the real quarter.

Where the profit went

Revenue

₹315.7 Cr

+39% YoY

Standalone EBITDA margin

8.2%

vs. 10.6–10.8% guidance

Consolidated EBITDA margin

4.3%

2-3 more quarters pressure expected

PAT

₹2.9 Cr

-80.5% YoY

Three factors crushed profitability despite revenue growth: raw material inflation (copper, steel cost pressures persist), unfavorable product mix (transformers, the lower-margin workhorse, account for 61% of revenue), and Elventive France integration drag (the French subsidiary is burning roughly ₹10 Cr per quarter and expected to do so for 4–5 more quarters before turnaround). Management flagged this as a 3–5 quarter margin headwind when guiding last quarter, but the depth of the PAT decline—80.5% despite 39% revenue growth—signals structural pressure, not cyclical miss. Standalone margin of 8.2% is 240 basis points below guidance; consolidated margins at 4.3% reflect Elventive's losses dragging the entire group down.

Claims vs. what holds up

Management's on-call claims, graded
  • "Highest ever quarterly and half-yearly revenue on consolidated basis." (₹315.7 Cr Q2; ₹574.1 Cr H1)

  • "FY27 30% revenue growth maintained." (Q2 39% YoY; H1 29.9% YoY—on track or ahead)

  • "Propulsion field trials completion in coming months." (Updated: 30,000 km done; completion expected before Q4—1–2 quarter slip)

  • "Standalone EBITDA margin 10.6–10.8%." (Actual: Q2 8.2%; H1 9.2%)

  • "Elventive France margins constrained 3–5 quarters toward breakeven." (On track: ~₹10 Cr/qtr loss expected for 4–5 quarters)

Revenue guidance held up; margin guidance did not. The propulsion timeline slip is subtle but material: management said "completion in coming months" on the last call; now they're guiding "before Q4," which implies 1–2 quarters of delay. That pushes first revenue recognition further into FY28, extending the near-term pain window.

What changed on this call

Major shifts vs. prior quarter

Propulsion field trials timeline

30,000 km done; completion now expected Q3-end/Q4 vs. prior 'coming months.' Implies 1–2 quarter slip and revenue contribution pushed to H2 FY27 / FY28.

Downgrade

EBITDA margin path

Q2 8.2% vs. 10.6–10.8% guidance. Management now guides 2–3 more quarters of pressure before stabilization. Recovery not expected until H2 FY27 or beyond.

Downgrade

Order book

Fell from ₹1,100 Cr (prior Q2) to ₹795 Cr (27% decline). Railway budget diversion to defense sectors cited. Signals near-term revenue visibility risk.

Downgrade

Copper conductor backward integration

Now generating external revenue: CTC sales ₹588 M (up from ₹395 M), with ~₹20 M external sales to other transformers customers. Railway CTC and PICC approvals unlock 500-ton capacity expansion.

Upgrade

Elventive France confirmed as multi-year drag

Expected loss ~₹10 Cr/qtr for 4–5 quarters. New leadership in place; 2 new customers and 1 new product line in trial. Opens EU/US market access but requires patience.

Neutral (expected)

The bull-bear ledger

  • Revenue growth 39% YoY; beats 30% FY27 guidance

  • Propulsion field trials 30,000 km completed; product performing well in tests

  • Railway electrification and propulsion addressable market: 1,000–1,400 systems (20% of total Railway market minimum)

  • Copper backward integration now contributing external revenue; Railway approvals widened scope

  • U.S. mining IGBT converter delivered ahead of schedule; more orders expected

  • PAT -80.5% YoY despite revenue growth—structural profitability issue, not cyclical

  • EBITDA margin 240 bps below guidance; 2–3 more quarters of pressure expected

  • Order book declined 27% due to Railway budget diversion to defense sectors

  • Transformers (61% of revenue) low-margin; product mix deterioration weighing on overall margins

  • Elventive France expected to lose ₹10 Cr/qtr for 4–5 more quarters; multi-year drag confirmed

  • Propulsion no revenue yet; 1–2 quarter slip on timeline; still dependent on vendor approvals

Risks ranked by holder concern

What should actually worry a shareholder, in order

Profitability collapse amid cost inflation

High

PAT -80.5% YoY despite revenue growth signals structural margin pressure (not cyclical). Raw material cost inflation, unfavorable product mix (transformers 61%, lower margin), and Elventive losses (~₹10 Cr/qtr) are expected to persist 2–3 more quarters. If margin recovery is slower or weaker than expected, ROE and cash generation remain impaired.

Propulsion execution and timeline risk

High

Field trials 30,000 km done but completion now expected Q3-end/Q4 vs. prior 'coming months'—a 1–2 quarter slip. No revenue yet. ~38 systems in order pipeline but development vendor orders stuck due to vendor list restructuring. Product is ahead of schedule in U.S. mining but domestic Railway revenue remains uncertain and delayed.

Order book decline and Railway demand curtailment

Medium

Order book fell 27% (₹1,100 Cr → ₹795 Cr). Railway budget diversion to defense sectors cited as reason. Near-term revenue visibility impacted. If defense priority persists, Railway capex recovery timeline extends, pushing revenue growth below guidance.

Elventive France multi-year drag on consolidated profitability

Medium

Expected loss ~₹10 Cr/qtr for 4–5 more quarters. High labor cost structure in France. If turnaround is slower or less profitable than expected, consolidated margins and ROE remain suppressed longer. M&A integration risks (talent loss, customer attrition) are material.

Product mix deterioration and margin compression persistence

Medium

Transformers 61% of revenue but lower EBITDA margin. Propulsion margin expected low for 2–3 quarters initially. New products (CTC, IGBT converters) still ramp-stage. If mix doesn't improve as fast as guided, margin recovery is further delayed and weaker than expected.

Raw material cost inflation unresolved

Medium

Copper and steel cost pressures persist. No clear visibility on moderation. CTC backward integration is a hedge, but limited near-term margin relief. If inflation accelerates or persists, gross margins compress further.

How the street is positioned

The market didn't buy the revenue beat story. HIRECT's stock fell 3.72% on day 1 and 1.62% by day 3 post-announcement (pre-result close ₹908.95; current ₹862). The decline held—the pop didn't fade—suggesting the fundamental read is that margin collapse outweighs revenue growth. That verdict aligns with our analysis: headline growth masks structural profitability issues that require 2–3 more quarters to stabilize.

Valuation context: The stock is now 38.4% below its all-time high, trading below all three key moving averages (SMA20 ₹947.5, SMA50 ₹1,086.71, SMA200 ₹1,003.48). RSI at 29 signals oversold technicals. Volume is increasing, which could signal either capitulation or accumulation; too early to call. The stock is up 52.5% from its 52-week low (₹565.2), suggesting a retracement from prior lows but not yet a recovery to prior confidence levels.

Ownership: FII holdings rose 0.27 pp to 6.84% (Q2 vs. Q1); DII added 2.96 pp to 3.16%—some institutional buying into weakness. Promoter shareholding fell 1.33 pp to 42.59%, a minor trim but worth noting given the stock's drawdown from all-time high. No major block sales signaled, so this doesn't read as panic exit; more consistent with normal rebalancing.

The debate

The honest read: HIRECT is a high-conviction long-term story (propulsion, Railway electrification, backward integration, global scale via Elventive) that is grinding through a painful 2–3 quarter near-term transition. Revenue is growing at 39%—genuine and ahead of guidance. But profitability is severely compromised by raw material inflation, unfavorable product mix, and a French acquisition losing ₹10 Cr/qtr. Management's guidance on margin recovery—"maybe 2 quarters, maybe challenging, maybe Q4, maybe one quarter later"—reads as uncertain on specifics, which is a yellow flag. The debate hinges on whether management can stabilize and recover margins within 2–3 quarters while propulsion field trials remain incomplete and dependent on Railway tender approvals.

The stock's 38% drawdown from all-time high is not irrational given the profitability collapse, but institutional buying (DII +2.96 pp) into the weakness suggests some believe the valuation now reflects the near-term pain. That's a reasonable intermediate view—but it requires confidence that management's 2–3 quarter margin recovery timeline holds and that propulsion doesn't slip further. If either breaks, downside is real.

What to watch next

Three things that resolve the debate by Q3
  • 1 · Q3 EBITDA margin and propulsion field trials completion

    Watch standalone EBITDA margin in Q3 (guidance: should show early stabilization signs if 2–3 quarter pressure story is real). Propulsion trials completion: management said 'before Q4,' so expect a detailed progress update on 30,000 km-plus distance and expected completion date. If trials slip into Q4 or beyond, re-rate risk down.

  • 2 · Order book recovery and Railway tender inflow

    Order book collapsed 27% in Q2. Watch Q3 order inflow from PLW and CLW tenders (management said these are 'in advanced stage' and expect 'quantities shortly'). If order book stabilizes or recovers toward ₹1,000 Cr+, it signals Railway demand is normalizing. If it stays below ₹800 Cr, defense budget diversion may be more persistent than expected.

  • 3 · Elventive France customer and revenue traction

    Elventive onboarded 2 new customers and 1 new product line (in trial) but still expected to lose ~₹10 Cr/qtr. Watch for revenue contribution from these new customers and product line in Q3. If revenue ramps faster than loss shrinks, the 4–5 quarter turnaround timeline may compress. If loss persists at ₹10 Cr/qtr or higher, re-rate the turnaround timeline further out.

HIRECT delivered record 39% YoY revenue growth, but profitability collapsed 80.5% due to raw material inflation, product mix deterioration, and Elventive France integration losses. The long-term transformation narrative (propulsion, backward integration, global scale) is credible and structurally sound. But the near-term—2–3 more quarters—is a grind: flat to negative earnings, margin recovery uncertain, propulsion timeline slipped 1–2 quarters, and order book collapsed 27%.

The stock's 38% drawdown from all-time high is not irrational, and institutional accumulation into the weakness suggests some see value. But this is not a classic 'margin trough beats expectations' play. It's a 'execution consistency and timeline management' story. Management's vague guidance on margin recovery ('maybe 2 quarters, maybe challenging, maybe Q4, maybe one quarter later') signals uncertainty on specifics, which is the real risk.

The single number to track from here is consolidated EBITDA margin. If Q3 shows early stabilization (trending back toward 6–7% from Q2's 4.3%), the 2–3 quarter thesis holds and risk/reward shifts to upside. If it stays flat or deteriorates, re-rate the recovery timeline further out and brace for downside. Propulsion field trials completion and order book recovery are secondary tells; margin is the lead indicator.

Informational and educational content only. Not investment advice.